Effects of intravenous prostaglandin E1 on pain and body temperature in patients with post-herpetic neuralgia

Pain Medicine

Volumn 11, Issue 4, 2010, Pages 609-616

  Kanai, Akifumi ^a   Wang, Guoqin ^b   Hoshi, Keika ^b   Okamoto, Hirotsugu ^a  

^a Department of Anaesthesiology ^*  (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Herpes Zoster; Post Herpetic Neuralgia; Prostaglandin E1; Temperature

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; IFENPRODIL; MEXILETINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; ALLODYNIA; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTENSION; MALE; NAUSEA; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; SKIN TEMPERATURE; TYMPANIC TEMPERATURE; VASCULITIS; VISUAL ANALOG SCALE;

EID: 77952844839     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00825.x     Document Type: Article

References (27)

1. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. Br Med J 2003, 326:748-50.
2. Kost RG, Straus SE. Postherpetic neuralgia-Pathogenesis, treatment, and prevention. N Engl J Med 1996, 335:32-42.
3. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med 2005, 2:628-44.
4. Lázaro C, Caseras X, Baños JE. Postherpetic neuralgia: A descriptive analysis of patients seen in pain clinics. Reg Anesth Pain Med 2003, 28:315-20. Catalonian Group for the Study of Postherpetic Neuralgia
5. Choi B, Rowbotham MC. Effect of adrenergic receptor activation on post-herpetic neuralgia pain and sensory disturbances. Pain 1997, 69:55-63.
6. Colding A. The effect of sympathetic blocks on herpes zoster. Acta Anaesthesiol Scand 1969, 13:113-41.
7. Abadir AR, Kraynack BJ, Mayda J, Gintautas J. Postherpetic neuralgia: Response to topical clonidine. Proc West Pharmacol Soc 1996, 39:47-8.
8. Kotani N, Kushikata T, Hashimoto H. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000, 343:1514-9.
9. Young W, Flamm ES. Effect of high-dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg 1982, 57:667-73.
10. De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: A double-blind crossover placebo-controlled study. Pain 1996, 65:45-51.
11. Trubestein G, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in chronic arterial disease: A multicenter study. Prog Clin Biol Res 1987, 242:445-51.
12. Iwamoto J, Takeda T, Ichimura S. Effect of administration of lipoprostaglandin E(1) on physical activity and bone resorption in patients with neurogenic intermittent claudication. J Orthop Sci 2001, 6:242-7.
13. Shindo H, Tawata M, Inoue M. The effect of prostaglandin E1 αCD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy. Diabetes Res Clin Pract 1994, 24:173-80.
14. Kanai A, Osawa S, Suzuki A, Ishimaru R, Hoka S. Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. Pain Med 2007, 8:36-40.
15. Fujita M, Hatori N, Shimizu M. Neutralization of prostaglandin E1 intravenous solution reduces infusion phlebitis. Angiology 2000, 51:719-23.
16. Kawamura A, Matsukawa T, Ozaki M. Use of modified infrared aural canal thermometers during cardiac surgery. Masui 2000, 49:792-5. in Japanese
17. Kanai A, Kumaki C, Niki Y. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia. Pain Med 2009, 10:902-9.
18. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain 2000, 16:S12-20.
19. Scheffler P, de la Hamette D, Leipnitz G. Therapeutic efficacy of intravenously applied prostaglandin E1. VASA 1989, 28:19-25. suppl
20. Rowbotham MC, Fields HL. Post-herpetic neuralgia: The relation of pain complaint, sensory disturbance, and skin temperature. Pain 1989, 39:129-44.
21. Cohrs RJ, Gilden DH, Mahalingam R. Varicella zoster virus latency, neurological disease and experimental models: An update. Front Biosci 2004, 1:751-62.
22. Leal-Berumen I, O'Byrne P, Gupta A, Richards CD, Marshall JS. Prostanoid enhancement of interleukin-6 production by rat peritoneal mast cells. J Immunol 1995, 154:4759-67.
23. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004, 75:234-41.
24. Bassil AK, Borman RA, Jarvie EM. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008, 154:126-35.
25. Siegel RJ, Shah PK, Nathan M, Rodriguez L, Shell WE. Prostaglandin E1 infusion in unstable angina: Effects on anginal frequency and cardiac function. Am Heart J 1984, 108:863-8.
26. Inoue K. ATP receptors of microglia involved in pain. Novartis Found Symp 2006, 276:263-72. discussion 273-81
27. Chuai M, Ogata T, Morino T. Prostaglandin E1 analog inhibits the microglia function: Suppression of lipopolysaccharide-induced nitric oxide and TNF-alpha release. J Orthop Res 2002, 20:1246-52.